Skip to main content
Press Release/Announcement

FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor).

MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; July 30, 2015.

Save
Print
August 12, 2015
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; July 30, 2015.

Look-alike and sound-alike drug names can contribute to confusion and result in medication errors. To raise awareness of potential wrong-patient errors due to similarity between two proprietary names, this announcement describes near misses with the drugs at the prescribing and dispensing stage and suggests clinicians use the generic names for the medications to reduce risk of patient harm.